| |
| |
|
| Insider
Information: |
Gosebruch Henry O |
| Relationship: |
|
| City: |
North Chicago |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
553,968 |
|
|
Indirect Shares
|
324,586 |
|
|
| Direct
Value |
$11,311,622 |
|
|
|
Indirect Value
|
$10,688,277 |
|
|
| Total
Shares |
878,554 |
|
|
| Total
Value |
$21,999,899 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
4
|
|
Stock
price went up :
|
1
|
3
|
| Stock
price went down : |
2
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
3.0
|
| Percentage
Gain/Loss : |
 -29.7%
|
 14.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Abbvie Inc. |
ABBV |
EVP, Chief Strategy Of... |
2022-05-16 |
41,623 |
2022-05-16 |
57,138 |
Premium* |
|
|
Aptinyx Inc. |
APTX |
Director |
2019-10-04 |
0 |
2020-01-10 |
125,000 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
Director |
2023-05-09 |
50,000 |
2023-05-09 |
0 |
Premium* |
|
|
Neumora Therapeutics, Inc. |
NMRA |
|
2024-02-14 |
462,345 |
2024-02-14 |
142,448 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NMRA |
Neumora Therapeutics, Inc... |
President & CEO |
• • – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
462,345 |
0 |
- |
|
| NMRA |
Neumora Therapeutics, Inc... |
President & CEO |
• • – |
2023-09-19 |
4 |
B |
$12.62 |
$189,371 |
I/I |
15,000 |
15,000 |
0.01 |
% |
|
| NMRA |
Neumora Therapeutics, Inc... |
President & CEOOfficer |
• • – |
2023-09-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
127,448 |
|
- |
|
| NMRA |
Neumora Therapeutics, Inc... |
President & CEOOfficer |
• • – |
2023-09-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
382,345 |
|
- |
|
| SLRN |
Acelyrin, Inc. |
Director |
– • – |
2023-05-09 |
4 |
B |
$18.00 |
$900,000 |
D/D |
50,000 |
50,000 |
2.39 |
% |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2022-05-16 |
4 |
OE |
$54.86 |
$4,606,046 |
D/D |
83,960 |
100,583 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2022-05-16 |
4/A |
S |
$155.00 |
$13,013,800 |
D/D |
(83,960) |
41,623 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2022-05-16 |
4/A |
OE |
$54.86 |
$4,606,046 |
D/D |
83,960 |
125,583 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2022-05-16 |
4 |
S |
$155.00 |
$13,013,800 |
D/D |
(83,960) |
16,623 |
0 |
% |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2022-03-01 |
4 |
S |
$147.54 |
$2,223,836 |
D/D |
(15,000) |
41,623 |
0 |
% |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2022-03-01 |
4 |
S |
$146.81 |
$3,682,189 |
D/D |
(25,000) |
16,623 |
0 |
% |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2022-03-01 |
4/A |
S |
$146.81 |
$3,682,189 |
I/I |
(25,000) |
53,500 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2022-02-25 |
4 |
D |
$149.54 |
$4,509,528 |
D/D |
(30,156) |
56,623 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2022-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
68,068 |
86,779 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2021-09-07 |
4 |
GA |
$0.00 |
$0 |
I/I |
30,000 |
78,500 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2021-09-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,000 |
18,711 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2021-02-28 |
4 |
D |
$107.74 |
$2,460,027 |
D/D |
(22,833) |
48,711 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
51,538 |
71,544 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2020-11-20 |
4 |
S |
$98.83 |
$3,975,046 |
D/D |
(40,000) |
20,006 |
0 |
% |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2020-04-06 |
4 |
GA |
$0.00 |
$0 |
I/I |
18,500 |
48,500 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2020-04-06 |
4 |
GD |
$0.00 |
$0 |
D/D |
18,500 |
60,006 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2020-02-28 |
4 |
D |
$85.42 |
$2,224,166 |
D/D |
(26,038) |
78,506 |
0 |
- |
|
| ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
• – – |
2020-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
58,781 |
104,544 |
0 |
- |
|
| APTX |
Aptinyx Inc. |
Director |
– • – |
2020-01-10 |
4 |
B |
$3.00 |
$75,000 |
I/I |
25,000 |
125,000 |
2.1 |
% |
|
| APTX |
Aptinyx Inc. |
Director |
– • – |
2019-10-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
100,000 |
100,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
